Blood Plasma Fractionation Market Isolating Therapeutic Proteins
Blood plasma, the liquid portion of blood that makes up about 55% of its total volume, is essential in medical treatments. Plasma fractionation is the process of separating its various components using specialized techniques. These components include coagulation factors like factor VIII, factor IX, prothrombin complex, Von Willebrand factor, fibrinogen, immunoglobulins, protease inhibitors, anticoagulants, and albumin. These plasma-derived products are critical in treating life-threatening conditions such as trauma, congenital disorders, immunologic diseases, and infections.
The increasing prevalence of immunological disorders, trauma, and blood disorders has led to a higher demand for blood plasma. For instance, albumin is vital in treating trauma, immunoglobulins are used for immunologic conditions, coagulation factors are essential in managing bleeding disorders like hemophilia, and protease inhibitors are used for treating emphysema. Additionally, growing blood donations and increasing awareness of plasma-based therapies are further driving market growth.
Blood Plasma Fractionation Market Trends
Several recent developments highlight the growth of the blood plasma fractionation market:
- In August 2024, Ma’ruf Amin, the Vice President of Indonesia, urged the Indonesian Red Cross (PMI) and other stakeholders to develop a local plasma fractionation program to reduce the dependency on imported plasma-derived products, ensuring more sustainable access to safe and reliable blood products in Indonesia.
- In December 2023, PlasmaGen Biosciences secured Rs 225 crore from UK-based Artian Investments to expand internationally, develop new products, and fund its operational needs.
- In March 2023, CSL opened a new $470 million plasma fractionation facility, which significantly increased its capacity to convert donated plasma into life-saving medicines.
Opportunities in the Blood Plasma Fractionation Market
The rising demand for blood plasma products has spurred innovation in the field, leading to improvements in patient care and treatment outcomes. Researchers are exploring new fractionation techniques to isolate plasma components more efficiently and investigating the therapeutic potential of plasma products for treating various disorders. In low- and middle-income countries, where large-scale plasma donations may be scarce, smaller-scale fractionation methods are gaining traction. For example, ethanol is traditionally used as a precipitant in fractionation, but efforts to remove ethanol are helping to streamline small-scale processes using single-use equipment for quick deployment. Additionally, continuous manufacturing techniques are being explored to maintain efficiency and throughput without requiring large-scale facilities. Automation is also on the rise in plasma fractionation, helping to improve processes like plasma harvesting and cleaning.
Challenges in the Blood Plasma Fractionation Market
One of the main challenges facing the blood plasma fractionation market is the high initial investment required for equipment and infrastructure. Large-scale fractionation facilities and advanced technologies can be expensive, with single-use filtration costing up to $500 per gram, while plasma products can be priced as high as $150,000 per gram. This price disparity can make it difficult for small-scale manufacturers to afford the necessary equipment. Another significant hurdle is the need for a continuous, reliable supply of large volumes of plasma to meet growing demand, which remains a challenge in many regions.
Recent Developments in the Blood Plasma Fractionation Market
- In February 2024, GC Biopharma became the first Korean company to get regulatory approval for a blood plasma product, Alyglo, for marketing in the US market.
- In November 2023, Grifols announced that it received approval from the US FDA for its new immunoglobulin purification and filling facility for producing Gamunex-C at its Clayton manufacturing campus. The company manufactures an additional 16 million grams of the therapy annually, with a total global capacity of 60 million grams.
Top Companies in the Blood Plasma Fractionation Market
- ADMA Biologics, Inc.
- Baxter International, Inc.
- Bio Products Laboratory
- Biotest AG
- CSL
- GC Biopharma
- Grifols, S.A.
- Kedrion Biopharma
- LFB S.A.
- OctaPharma
- PlasmaGen Biosciences
- Sanquin
- SK Plasma
- Takeda Pharmaceutical Co. Ltd.
Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/blood-plasma-fractionation-market-sizing
To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5286
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.
Visit Dental Specifics: https://www.towardsdental.com
Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare